Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer
Triple–negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer with a poor response rate to conventional systemic treatment and high relapse rates. Members of the natural killer group 2D ligand (NKG2DL) family are expressed on cancer cells but are typically absent from he...
Main Authors: | Polina Kaidun, Samuel J. Holzmayer, Sarah M. Greiner, Anna Seller, Christian M. Tegeler, Ilona Hagelstein, Jonas Mauermann, Tobias Engler, André Koch, Andreas D. Hartkopf, Helmut R. Salih, Melanie Märklin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/17/13156 |
Similar Items
-
Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
by: Melanie Märklin, et al.
Published: (2019-05-01) -
Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas
by: Ilona Hagelstein, et al.
Published: (2021-04-01) -
The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer
by: Ge Tan, et al.
Published: (2023-08-01) -
Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome
by: Anna Seller, et al.
Published: (2024-04-01) -
Romidepsin Enhances the Killing Ability of NKG2D-CAR-T Cells through Enhanced Expression of NKG2DL against Ovarian Cancer Cells
by: Liang Wang, et al.
Published: (2022-09-01)